S
Samedy Ouk
Researcher at University of California
Publications - 27
Citations - 3221
Samedy Ouk is an academic researcher from University of California. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 10, co-authored 24 publications receiving 2865 citations. Previous affiliations of Samedy Ouk include University of California, Los Angeles & Cornell University.
Papers
More filters
Journal ArticleDOI
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran,Samedy Ouk,Nicola J. Clegg,Yu Chen,Philip A. Watson,Vivek K. Arora,John Wongvipat,Peter Smith-Jones,Dongwon Yoo,Andrew Kwon,Teresa Wasielewska,Derek S. Welsbie,Charlie D. Chen,Celestia S. Higano,Tomasz M. Beer,David T. Hung,Howard I. Scher,Michael E. Jung,Charles L. Sawyers +18 more
TL;DR: The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.
Journal ArticleDOI
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg,John Wongvipat,James Joseph,Chris Tran,Samedy Ouk,Anna Dilhas,Yu Chen,Kate Grillot,Eric D. Bischoff,Ling Cai,Anna Aparicio,Steven Dorow,Vivek K. Arora,Gang Shao,Jing Qian,Hong Zhao,Guangbin Yang,Chunyan Cao,John Sensintaffar,Teresa Wasielewska,Herbert Mark R,Celine Bonnefous,Beatrice Darimont,Howard I. Scher,Peter Smith-Jones,Mark Klang,Nicholas D. Smith,Elisa de Stanchina,Nian Wu,Ouathek Ouerfelli,Peter J. Rix,Richard A. Heyman,Michael E. Jung,Charles L. Sawyers,Jeffrey H. Hager +34 more
TL;DR: ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer.
Journal ArticleDOI
Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
Michael E. Jung,Samedy Ouk,Dongwon Yoo,Charles L. Sawyers,Charlie Chen,Chris Tran,John Wongvipat +6 more
TL;DR: A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.
Patent
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
TL;DR: A hydantoin compound is a compound useful for the prevention or treatment of hyperproliferative diseases or disorders as mentioned in this paper, but it is not suitable for the treatment of cancer.
Journal ArticleDOI
A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.
Yusuke Shono,Andrea Z. Tuckett,Samedy Ouk,Hsiou-Chi Liou,Grégoire Altan-Bonnet,Jennifer Tsai,Jennifer E. Oyler,Odette M. Smith,Mallory L. West,Natalie V. Singer,Ekaterina Doubrovina,Dmitry Pankov,Chandresh V. Undhad,George F. Murphy,Cecilia Lezcano,Chen Liu,Richard J. O'Reilly,Marcel R.M. van den Brink,Johannes L. Zakrzewski +18 more
TL;DR: This work developed a novel strategy to ameliorate GVHD while preserving graft-versus-tumor activity by small molecule-based inhibition of the NF-κB family member c-Rel, validating c-rel as a promising target for immunomodulatory therapy and demonstrating the feasibility and efficacy of pharmaceutical inhibition of c- Rel activity.